|
Colorectal Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
The expression of p-S6K1 was upregulated in CRC tissues and NLRP3 expression level was positively associated with the p-S6K1 level.
|
31757663 |
2020 |
|
Colorectal Carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
The level of p‑S6K1 was markedly high in CRC tissues and Rab1A expression level had a positive association with p‑S6K1 level.
|
30896866 |
2019 |
|
Colorectal Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
miR‑5191 functions as a tumor suppressor by targeting RPS6KB1 in colorectal cancer.
|
31485593 |
2019 |
|
Colorectal Carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
|
28153010 |
2017 |
|
Colorectal Carcinoma
|
0.340 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
We measured mTOR activity with immunohistochemistry for p-mTOR and its downstream effectors p(T389)-p70S6K1, p-S6, and p-4E-BP1 in 31 cases of PCNSL and 51 cases of systemic diffuse large B-cell lymphoma (DLBCL) and evaluated alternative S6 phosphorylation pathways with p-RSK, p(T229)-p70S6K1, and PASK antibodies.
|
29361117 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Taken together, amplified RPS6KB1 and CDC2 are potential biomarkers for the aggressive DLBCL, particularly in HIV+/EBV+ patients.
|
23330000 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
RPS6KB1 and CDC2 overexpression is common in DLBCL.
|
19223503 |
2009 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
RPS6KB1 and CDC2 overexpression is common in DLBCL.
|
19223503 |
2009 |
|
Ceroid lipofuscinosis, neuronal 1, infantile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol.
|
21224254 |
2011 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
CTD_human |
Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.
|
19289642 |
2009 |
|
Left Ventricular Hypertrophy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.
|
19289642 |
2009 |
|
Atrophic
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Atrophic remodeling of the transplanted rat heart.
|
16391472 |
2006 |
|
Obesity
|
0.260 |
Biomarker
|
disease |
BEFREE |
Pharmacological targeting of S6K1 may improve the outcome of exercise-based interventions in obesity and diabetes.
|
29107291 |
2017 |
|
Obesity
|
0.260 |
Biomarker
|
disease |
BEFREE |
We have previously shown that Sam68-deficient mice have a lean phenotype and are protected against dietary-induced obesity due to defects in mTOR and S6K1 alternative splicing.
|
29137239 |
2017 |
|
Obesity
|
0.260 |
Biomarker
|
disease |
BEFREE |
These findings define an S6K1-dependent mechanism in early adipogenesis, contributing to the promotion of obesity.
|
27151441 |
2016 |
|
Obesity
|
0.260 |
AlteredExpression
|
disease |
BEFREE |
The increased levels of S6K1 in obesity and its positive association with insulin resistance and inflammation suggest a role for this protein in the changes that take place in VAT in obesity establishing a link between inflammation and a higher risk for the development of metabolic diseases.
|
25118997 |
2015 |
|
Obesity
|
0.260 |
Biomarker
|
disease |
BEFREE |
Earlier, we reported that S6K1(-/-) mice have reduced body fat mass, have elevated rates of lipolysis, have severely decreased adipocyte size, and are resistant to high fat diet (HFD)-induced obesity.
|
20493810 |
2010 |
|
Obesity
|
0.260 |
Biomarker
|
disease |
RGD |
Time-course studies also revealed that mTOR and S6K1 activation by insulin was accelerated in tissues of obese rats, in association with increased inhibitory phosphorylation of insulin receptor substrate-1 (IRS-1) on Ser636/Ser639 and impaired Akt activation.
|
15604215 |
2005 |
|
Obesity
|
0.260 |
PosttranslationalModification
|
disease |
BEFREE |
In vitro studies with rapamycin suggest that mTOR/S6K1 overactivation contributes to elevated serine phosphorylation of IRS-1, leading to impaired insulin signaling to Akt in liver and muscle of this dietary model of obesity.
|
15604215 |
2005 |
|
Muscular Atrophy
|
0.200 |
Biomarker
|
phenotype |
RGD |
Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway.
|
17885021 |
2008 |
|
Cardiomegaly
|
0.200 |
Biomarker
|
phenotype |
RGD |
Disparate regulation of signaling proteins after exercise and myocardial infarction.
|
16540832 |
2006 |
|
Polycystic Kidney Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
|
16221708 |
2006 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
RGD |
Disparate regulation of signaling proteins after exercise and myocardial infarction.
|
16540832 |
2006 |
|
Cardiomyopathy, Dilated
|
0.200 |
Biomarker
|
group |
RGD |
Rapamycin ameliorates experimental autoimmune myocarditis.
|
16043946 |
2005 |